Where does Insilico Medicine IP Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Insilico Medicine IP Limited ranks #8,835 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Insilico Medicine IP Limited hold?

Insilico Medicine IP Limited holds 36 US utility patents granted between 2020 and 2025, spanning 16 technology areas.

What is Insilico Medicine IP Limited's Innovation Score?

Insilico Medicine IP Limited has an Innovation Score of 59.3 out of 100 (top 4% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Insilico Medicine IP Limited focus on?

Insilico Medicine IP Limited's top technology area is C07D (Heterocyclic Compounds) with 26 patents. Grants appear in 16 CPC subclasses total.

Is Insilico Medicine IP Limited's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Insilico Medicine IP Limited.

What does claim depth mean for Insilico Medicine IP Limited's patents?

Insilico Medicine IP Limited's patents average 21.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Insilico Medicine IP Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Insilico Medicine IP Limited

USPTO PatentsView assignee record - 36 granted patents across 16 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Insilico ranks #8,835 of 49,997 tracked US assignees by granted-patent volume, with 36 patents across 16 technology areas.

#8,835
of 49,997 US assignees by volume: Top 4%
by Innovation Score (59.3/100): 21.2
avg claims per patent

USPTO PatentsView assignee plate

Corpus R8835 · Foreign Corporation #8,835 · 36 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-SMALL 36 grants
UPPER-Q #8,835/49,997
PHOTO-FINISH Idemitsu Unitech
CPC-FOCUS C07D · 16 areas
INNOV-PAR 59.3/100
CLAIMS-DENSE 21.2 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Idemitsu Unitech Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Beijing Eswin… · near

59
Bristol-Myers Squibb · near

59
Insilico Medicine IP · this assignee

59
8ME Nova · near

59
Danisco US · near

59
3D Lighting… · lowest

7

What this shows Insilico's Innovation Score is 59.3/100 (top 4% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Insilico's grants concentrate

Insilico Medicine IP Limited is a focused PatentsView assignee: 16 CPC subclasses with 72.2% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2023 (10 grants) versus a trough of 2 in 2021. By volume, Insilico sits between Idemitsu Unitech Co., Ltd. and Ipsen Biopharm Limited.

Insilico's three-year grant acceleration

Insilico Medicine IP Limited shows 23 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Idemitsu Unitech

36
Indian Institute…

36
Innodisk

36
Inria—Institut Na…

36
Integenx

36
Interaxon

36
INV Nylon Chemica…

36
Ipsen Biopharm

36
Insilico Medicine… ◀

36

What this shows Insilico holds 36 patents at rank #8,831, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Insilico

By rank, the assignees closest to #8,831 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Insilico's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Insilico, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (59 here).

Beijing Eswin Computing Technology Co., Ltd. 59 Bristol-Myers Squibb Company 59 8ME Nova, LLC 59 Danisco US Inc. 59

Insilico's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

59 Top 4% higher than 96% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Insilico Medicine IP Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	3	8.3%
2021	2	5.6%
2022	5	13.9%
2023	10	27.8%
2024	8	22.2%
2025partial year	8	22.2%

Which technologies does Insilico Medicine IP Limited patent most?

C07D - Heterocyclic Compounds 26

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 18

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 15

G06N - Computing Arrangements Based ON Specific Computational Models 9

G16C - Computational CHEMISTRY; CHEMOINFORMATICS; Computational Materials Science 8

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 7

G06F - Electric Digital Data Processing 5

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 4

G06T - Image Data Processing OR Generation, IN General 2

G10L - Speech Analysis Techniques OR Speech SYNTHESIS; Speech RECOGNITION; Speech OR Voice Processing TECHNIQUES; Speech OR Audio Coding OR Decoding 2

G06V - Image OR Video Recognition OR Understanding 2

G09B - Educational OR Demonstration APPLIANCES; Appliances FOR Teaching, OR Communicating With, THE Blind, Deaf OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; Diagrams 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Top 15 of 16 technology areas

Where it ranks

Overall rank by patents

#8,835

of 49,997 tracked assignees

Innovation Score

59.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Insilico Medicine IP Limited's patent record in context - here's where to go next.

Insilico Medicine IP Limited's lead technology class is C07D (Heterocyclic Compounds), 72.2% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #8,835 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Insilico Medicine IP Limited against Idemitsu Unitech Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 59.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.